Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957546 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALOX5MTORCTSKCASR | |
| SCHEMBL24726844 | 0.86 | ALOX5 (0.40) | ALOX5MTORCTSKCASRGPR88 | |
| SCHEMBL956471 | 0.86 | ALOX5 (0.41) | L3MBTL1ALOX5 | |
| SCHEMBL956469 | 0.86 | ALOX5 (0.41) | L3MBTL1ALOX5 | |
| SCHEMBL14067608 | 0.84 | GPR88 (0.45) | L3MBTL1ALOX5MTORCTSKGPR88 | |
| SCHEMBL20741092 | 0.82 | DAGLA (0.41) | ALOX5MTORCTSKCASRRIPK1 | |
| SCHEMBL20741091 | 0.82 | DAGLA (0.41) | ALOX5MTORCTSKCASRRIPK1 | |
| SCHEMBL22327659 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CTSKCTSS | |
| SCHEMBL960788 | 0.81 | ALOX5 (0.45) | ALOX5MTORTRPM8 | |
| SCHEMBL13953680 | 0.81 | SLC6A4 (0.39) | L3MBTL1ALOX5MTORCTSKGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8575156-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | L3MBTL1 4021/4885ALOX5 1148/4885MTOR 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.